Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer
Open accessThe DOI matches its Crossref record; 89 of the 89 references it cites were found in a registry or an index; 17 of the 98 sources its claims cite were checked for support.
Abstract
Metastatic colorectal cancer remains a deadly malignancy and is the third leading cause of cancer-related death. The mainstay of treatment for metastatic colorectal cancer is chemotherapy, but unfortunately, even with recent progress, overall survival is still poor. Colorectal cancer is a heterogeneous disease, and the underlying genetic differences among tumors can define the behavior and prognosis of the disease. Given the limitations of cytotoxic chemotherapy, research has focused on developing targeted therapy based on molecular subtyping. Since the early 2000s, multiple targeted therapies have demonstrated efficacy in treating metastatic colorectal cancer and have received FDA approval. The epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), and DNA mismatch repair pathways have demonstrated promising results for targeted therapies. As new gene mutations and proteins involved in the oncogenesis of metastatic colorectal cancer are identified, new targets will continue to emerge. We herein provide a summary of the updated literature regarding targeted therapies for patients with mCRC.
Overview
CoChat Summary
TL;DR
This narrative review summarizes targeted therapy and immunotherapy options for metastatic colorectal cancer by molecular pathway, including EGFR, VEGF, HER2, immune checkpoint, and NTRK targets. It emphasizes molecular profiling, tumor sidedness, MSI status, and HER2/NTRK alterations as determinants of therapy selection, while noting resistance mechanisms and the need for better biomarkers.
Key findings
- EGFR-directed therapy benefits are limited mainly to left-sided KRAS wild-type tumors; in TAILOR, FOLFOX plus cetuximab improved overall survival versus FOLFOX alone (20.7 vs. 17.8 months), while the EPOC trial found median overall survival of 81.0 months with chemotherapy versus 55.4 months with cetuximab plus chemotherapy in operable liver metastases, leading the authors to advise against cetuximab in that setting.
- VEGF-pathway agents show survival gains in metastatic colorectal cancer: bevacizumab plus IFL improved median overall survival versus IFL alone (20.3 vs. 15.6 months); aflibercept plus FOLFIRI improved overall survival versus FOLFIRI (13.5 vs. 12.1 months); ramucirumab plus FOLFIRI improved overall survival versus placebo plus FOLFIRI (13.3 vs. 11.7 months); regorafenib improved median overall survival versus placebo (6.4 vs. 5.0 months); and fruquintinib improved overall survival versus placebo in FRESCO (9.3 vs. 6.6 months) and FRESCO-2 (7.4 vs. 4.8 months, p < 0.001).
- HER2 amplification occurs in approximately 3–5% of colorectal cancers; in MOUNTAINEER, tucatinib plus trastuzumab produced an objective response rate of 38.1%, and in DESTINY-CRC01, trastuzumab deruxtecan produced an objective response rate of 45.3%, median overall survival of 15.5 months, and progression-free survival of 6.9 months.
- In MSI-high tumors, pembrolizumab improved progression-free survival versus chemotherapy in KEYNOTE-177 (median 16.5 vs. 8.2 months, HR 0.60, p < 0.001), and first-line nivolumab plus ipilimumab in CheckMate 142 produced an objective response rate of 69%, disease control rate of 84%, and 13% complete response rate; atezolizumab added to FOLFOXIRI plus bevacizumab in AtezoTRIBE improved progression-free survival versus control (13.1 vs. 11.5 months, HR 0.69, p = 0.012).
Methods
- Broad literature review using MEDLINE/PubMed, with search ending 15 December 2023; search terms included “targeted therapy,” “colon cancer,” “colorectal cancer,” and “immunotherapy.”
- Inclusion prioritized clinical trials related to targeted therapy and immunotherapy for colorectal cancer metastasis; two authors performed initial review, and the senior author made final inclusion determinations.
- The paper is a narrative review, not a systematic review or meta-analysis.
Limitations
- Stated limitations: Not stated in the paper.
- Evident from the text: the review is broad and narrative rather than systematic, with no formal risk-of-bias assessment or quantitative synthesis, and the search ended in December 2023.
- Evident from the text: many included trials differ in setting, line of therapy, endpoints, and maturity; for example, overall survival data for sotorasib plus panitumumab were not yet available, and several phase 3 trials were ongoing, limiting direct cross-trial comparisons.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 The EGFR pathway demonstrates multiple targets, including the EGFR, RAS, BRAF V600E, and MEK. The figure was adapted from [13].](https://figures.cochat.ai/paper-figures/b0ade5266a6f49e994dd1e534ad50b9e/update-on-targeted-therapy-and-immunotherapy-for-metastatic-colorectal-cancer-figure-1.jpg)
![Figure 2 The VEGF pathway illustrates the mechanism through which the VEGF receptor elicits angiogenesis. The figure was adapted from [44].](https://figures.cochat.ai/paper-figures/bb5bbcee445247f5ac8ad7de596f52ef/update-on-targeted-therapy-and-immunotherapy-for-metastatic-colorectal-cancer-figure-2.jpg)
Verification
Claims the paper makes
13 Valid · 1 Not valid · 80 Not checked · 15 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“the median overall survival was 81.0 months in the chemotherapy group and 55.4 months in the cetuximab plus chemotherapy group.”
§ Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer > 4. The Epidermal Growth Factor Receptor Pathway > 4.1. Cetuximab
What the sources say
- Supportedcites [20] Bridgewater J.A. Pugh S.A. Maishman T. Eminton Z. Mellor J. Whitehead A. Stanton L. Radford M. Corkhill A. Griffiths G.O. Systemic Chemotherapy with or without Cetuximab in Patients with Resectable Colorectal Liver Metastasis (New EPOC): Long-Term Results of a Multicentre, Randomised, Controlled, Phase 3 Trial Lancet Oncol. 2020 21 398 411 10.1016/S1470-2045(19)30798-3 32014119 PMC7052737 source
The Results section of the New EPOC paper reports median overall survival of 81·0 months with chemotherapy alone and 55·4 months with chemotherapy plus cetuximab. The paper identifies the patients as having resectable colorectal liver metastases. (LLM, conf=0.95)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Pre-clinical studies and early trials have demonstrated improved responses to combined MEK and BRAF inhibition [37,38].”
§ Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer > 4. The Epidermal Growth Factor Receptor Pathway > 4.5. BRAF and MEK Inhibition
What the sources say
- Partly supportedcites [37] Corcoran R.B. Dias-Santagata D. Bergethon K. Iafrate A.J. Settleman J. Engelman J.A. BRAF Gene Amplification Can Promote Acquired Resistance to MEK Inhibitors in Cancer Cells Harboring the BRAF V600E Mutation Sci. Signal 2010 3 ra84 10.1126/scisignal.2001148 21098728 PMC3372405 sourceExperimental — accuracy not yet measured
The Results section reports that combined MEK and BRAF inhibition was more potent than either treatment alone in BRAF-mutant cancer cells. The Introduction describes favorable responses in early clinical trials of the inhibitors individually, not trials of the combination. This source therefore supports the preclinical part of the claim but not the claim about improved responses to combined treatment in early trials; page numbers were not provided. (LLM, conf=0.88)
- Partly supportedcites [38] Corcoran R.B. André T. Atreya C.E. Schellens J.H.M. Yoshino T. Bendell J.C. Hollebecque A. McRee A.J. Siena S. Middleton G. Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAFV600E-Mutant Colorectal Cancer Cancer Discov. 2018 8 428 443 10.1158/2159-8290.CD-17-1226 29431699 PMC5882509 sourceExperimental — accuracy not yet measured
The Introduction (page not provided) reports a modestly improved response rate of 12% in an early trial of combined BRAF and MEK inhibition. It says preclinical models showed improved pathway suppression, but does not say they showed improved responses. (LLM, conf=0.82)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“A post hoc analysis of the RAISE trial demonstrated that the greatest benefit of ramucirumab therapy was in patients with CEA ≤ 10 versus CEA > 10 [56].”
§ Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer > 5. The Vascular Endothelial Growth Factor Pathway > 5.3. Ramucirumab
What the sources say
- Supportedcites [56] Yoshino T. Obermannová R. Bodoky G. Garcia-Carbonero R. Ciuleanu T. Portnoy D.C. Kim T.W. Hsu Y. Ferry D. Nasroulah F. Baseline Carcinoembryonic Antigen as a Predictive Factor of Ramucirumab Efficacy in RAISE, a Second-Line Metastatic Colorectal Carcinoma Phase III Trial Eur. J. Cancer 2017 78 61 69 10.1016/j.ejca.2017.03.007 28412590 source
The Results report a larger overall-survival benefit with ramucirumab in the CEA ≤10 ng/ml subgroup than in the >10 ng/ml subgroup: 3.6 versus 0.8 months of median survival improvement. The Discussion likewise says the benefit was stronger at lower CEA values. The authors describe these as exploratory analyses requiring prospective confirmation. (LLM, conf=0.92)
boostedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“the CONSIGN study was a Phase IIIB study that evaluated the safety profile of regorafenib and demonstrated a reasonable toxicity profile for most patients [60].”
§ Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer > 5. The Vascular Endothelial Growth Factor Pathway > 5.4. Regorafenib
What the sources say
- Supportedcites [60] Van Cutsem E. Martinelli E. Cascinu S. Sobrero A. Banzi M. Seitz J.-F. Barone C. Ychou M. Peeters M. Brenner B. Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single-Arm, Open-Label Phase IIIb CONSIGN Study Oncologist 2019 24 185 192 10.1634/theoncologist.2018-0072 30190299 PMC6369948 source
The INTRODUCTION states CONSIGN (NCT01538680) 'was designed to characterize regorafenib safety in a larger patient population' in treatment-refractory mCRC, and the title/abstract frame it as the phase IIIb, single-arm, open-label study — matching the citing sentence's design and purpose. The DISCUSSION supplies the substance of 'reasonable toxicity profile for most patients': regorafenib-related TEAEs led to dose modifications in 60% but discontinuation in only 9%, 'suggesting that regorafenib-related TEAEs were managed with dose modifications, allowing patients to stay on therapy,' and the safety profile was 'consistent with results of the phase III trials.' The CONCLUSION echoes this while adding that high dose-reduction/interruption rates underscore the need for patient selection and AE management — a nuance, not a contradiction, of the paraphrase. (LLM, conf=0.80)
boosted- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“and the FDA has approved their use for these patients.”
§ Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer > 9. Tyrosine Receptor Kinase Fusions > 9.3. Summary
What the sources say
- Supportedcites [84] Doebele R.C. Drilon A. Paz-Ares L. Siena S. Shaw A.T. Farago A.F. Blakely C.M. Seto T. Cho B.C. Tosi D. Entrectinib in Patients with Advanced or Metastatic NTRK Fusion-Positive Solid Tumours: Integrated Analysis of Three Phase 1-2 Trials Lancet Oncol. 2020 21 271 282 10.1016/S1470-2045(19)30691-6 31838007 PMC7461630 source
The Introduction states that the FDA granted accelerated approval to larotrectinib for adults and children with solid tumours harbouring an NTRK fusion. The Discussion states that the FDA granted accelerated approval to entrectinib for the same patient group in August 2019. (LLM, conf=0.94)
- Supportedcites [85] Hong D.S. DuBois S.G. Kummar S. Farago A.F. Albert C.M. Rohrberg K.S. van Tilburg C.M. Nagasubramanian R. Berlin J.D. Federman N. Larotrectinib in Patients with TRK Fusion-Positive Solid Tumours: A Pooled Analysis of Three Phase 1/2 Clinical Trials Lancet Oncol. 2020 21 531 540 10.1016/S1470-2045(19)30856-3 32105622 PMC7497841 source
The Introduction states that the FDA approved larotrectinib for adults and children with advanced solid tumours harbouring an NTRK fusion, and similarly approved entrectinib for NTRK fusion-positive disease. This supports the cited statement about both drugs, subject to the paper’s stated advanced-tumour qualification for larotrectinib. (LLM, conf=0.93)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
59 more claims · 6 with their cited sources checked
Create a free account to see all 109 claims and to verify the 81 references still open.
- It may state two separate claims as one. 31
- Probably not a substantial claim. 11
- The quote only partly states this claim. 6
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer > 4. The Epidermal Growth Factor Receptor Pathway > 4.7. Summary
“For patients with KRAS C12C mutations, guidelines recommend the use of sotorasib or adagrasib.”
§ Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer > 4. The Epidermal Growth Factor Receptor Pathway > 4.6. RAS Inhibition
“Two therapies targeting KRAS G12C mutation are currently under investigation. Sotorasib irreversibly binds the KRAS G12C protein.”
Citations
Cites
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968 · cited 1×
“Another trial evaluated the use of bevacizumab as adjuvant therapy after surgery [51].”
BackgroundMutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674 · cited 1×
“Among patients with colorectal cancer, there is an approximately 10% incidence of BRAF mutation [36].”
BackgroundCunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035 · cited 2×
“Cetuximab was fi rst approved by the FDA in 2004 after a multicenter, randomized trial in Europe demonstrated promising results among patients with poor response to irinotecan-based regimens [15].”
BackgroundMethodCetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805019 · Cited by 3,877 · cited 1×
“The CRYSTAL trial was a multicenter, phase 3 trial evaluating FOLFIRI plus cetuximab versus FOLFIRI alone for patients with unresectable colorectal cancer [16].”
MethodColorectal cancer statistics, 2023
Siegel, R. L., Wagle, N. S., Cercek, A., Smith, R. A., & Jemal, A. (2023) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21772 · Cited by 3,733 · cited 2×
“Colorectal cancer (CRC) is the third most commonly diagnosed cancer in men and women in the United States and the third leading cause of cancer-related death [1].”
BackgroundMethodWild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7116 · Cited by 3,207 · cited 1×
“Patients must have KRAS wt tumors for panitumumab to be effective [22,23].”
BackgroundPembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer
André, T., Shiu, K.-K., Kim, T. W., Jensen, B. V., Jensen, L. H., Punt, C., Smith, D., Garcia-Carbonero, R., Benavides, M., Gibbs, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2017699 · Cited by 3,099 · cited 1×
“The Check-Mate 142 trial was a multinational, multicenter, phase 2 trial that evaluated nivolumab in patients with MSI high tumors refractory to chemotherapy.”
MethodSaltz, L. B., Clarke, S., Díaz-Rubio, E., Scheithauer, W., Figer, A., Wong, R., Koski, S., Lichinitser, M., Yang, T.-S., Rivera, F., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.9930 · Cited by 2,955
Grothey, A., Cutsem, E. V., Sobrero, A., Siena, S., Falcone, A., Ychou, M., Humblet, Y., Bouché, O., Mineur, L., Barone, C., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61900-x · Cited by 2,895 · cited 1×
“This multicenter, randomized trial in China compared fruquitinib to placebo in patients who had progressed on at least two lines of therapy but had not received a VEGF inhibitor.”
MethodOverman, M. J., McDermott, R., Leach, J. L., Lonardi, S., Lenz, H.-J., Morse, M. A., Desai, J., Hill, A., Axelson, M., Moss, R. A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30422-9 · Cited by 2,836 · cited 1×
“The AtezoTRIBE trial added atezolizumab to FOLFOXIRI plus bevacizumab among patients with microsatellite stable tumors to assess the hypothesis that FOLFOXIRI and bevacizumab may increase the immunogenicity of microsatellite stable tumors [82].”
Method
Cited by
Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer
Haynes, J., & Manogaran, P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26051988 · Cited by 82
“This type of targeted therapy is only effective in the absence of mutations in , HER2-positive) ) for CRC with BRAF-V600E mutation, used in combination with EGFR inhibitor cetuximab (Figure 2) [14,34].”
InfluentialImmunotherapy for colorectal cancer
Yu, B., Kang, J., Lei, H., Li, Z., Yang, H. C., & Zhang, M. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1433315 · Cited by 43
Rahman, M. A., & Ali, M. M. (2024) · Cancers · doi:10.3390/cancers16172975 · Cited by 28
Chang, W., Peng, J.-Y., Hong, C.-L., Li, P.-C., Chye, S. M., Lu, F., Lin, H.-Y., & Chen, C. (2025) · Antioxidants · doi:10.3390/antiox14070892 · Cited by 205
“…research emphasize the need for personalized therapeutic strategies, particularly for metastatic CRC. Targeted therapies directed at EGFR, VEGF, BRAF, and HER2, as well as immune checkpoint inhibitors (e.g., anti-PD-1), have demonstrated clinical benefit in biomarker-defined patient subgroups [23].”
Unraveling the complexities of colorectal cancer and its promising therapies – An updated review
Saha, S., Ghosh, S., Ghosh, S., Nandi, S., & Nayak, A. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113325 · Cited by 30
New insight in immunotherapy and combine therapy in colorectal cancer
Ji, K., Jia, H., Liu, Z., Yu, G., Wen, R., Zhang, T., Peng, Z., Man, W., Tian, Y., Wang, C., et al. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1453630 · Cited by 24
Neural influences in colorectal cancer progression and therapeutic strategies
Zeng, Z., Cai, S., Ye, C., Li, T., Tian, Y., Liu, E., Cai, J., Yuan, X., Yang, H., Liang, Q., et al. (2025) · International Journal of Colorectal Disease · doi:10.1007/s00384-025-04887-w · Cited by 19
Xia, K., Hu, W., Wang, Y., Chen, J., Hu, Z., An, C., Xu, P., Teng, L., Wu, J., Liu, L., et al. (2024) · Mechanobiology in Medicine · doi:10.1016/j.mbm.2024.100062 · Cited by 19
“40 However, the regulatory mechanism of the impact of changes in the physical properties (e.g., stiffness) of the tumor microenvironment, induced by peroxidation of the extracellular matrix by free radicals generated by the vigorous metabolism of tumor cells, on the invasion and metastasis of CCCs…”
Zhang, R., Lan, S., Jia, M., Liu, F., Wang, M., Jin, Q., Su, L., & Liu, G. (2025) · International Journal of Nanomedicine · doi:10.2147/ijn.s516926 · Cited by 19
NAD+/SIRT1 pathway regulates glycolysis to promote oxaliplatin resistance in colorectal cancer
Niu, Y., Xiang, M.-D., Yang, W., Fang, Y., Qian, H., & Sun, Y.-K. (2025) · World Journal of Gastroenterology · doi:10.3748/wjg.v31.i11.100785 · Cited by 15
Boka, H. J., Engel, R. M., Georges, C., McMurrick, P. J., & Abud, H. E. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02327-5 · Cited by 15
Precision Medicine for Metastatic Colorectal Cancer: Where Do We Stand?
Underwood, P. W., & Pawlik, T. M. (2024) · Cancers · doi:10.3390/cancers16223870 · Cited by 15
“Current efforts to improve survival for mCRC are focused on personalized approaches with targeted therapies toward genetic mutations [13].”
Self-citationTwardowska, M., Łyskowski, A., Misiorek, M., Szymaszek, Ż., Wołowiec, S., Dąbrowska, M., & Uram, Ł. S. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26041594 · Cited by 14
Chen, W., Cheng, Q., Li, N., Gu, K., Zhao, H., & Na, H. (2025) · American Journal of Cancer Research · doi:10.62347/wbjl4045 · Cited by 13
Xu, H., Wang, H., Xiang, Y., Grønlien, I., Torvund, A. G. S., Xomalis, A., & Zhao, Z. (2025) · Biomedical Optics Express · doi:10.1364/boe.557218 · Cited by 11
Cao, J., Hang, K., Zhang, H., Wu, Z., Guo, Z., Men, J., Tian, J., & Li, K. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177964 · Cited by 13
Duan, Y., Li, A., Miao, D., Tan, D., Wang, K., & Shi, J. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1714954 · Cited by 15
Chen, W., Zhu, P., Chen, Y., & Sun, G. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1568755 · Cited by 11
Advanced oral therapies for colorectal cancer via nanomedicine and microbiota modulation
Wang, Y., Chen, C., Xiao, X. H., Kang, Y., He, J., Beloqui, A., & Xu, Y. (2025) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2025.115741 · Cited by 10
Liu, J., Zhang, X., Yang, M., & Zhang, X. (2024) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-024-05736-z · Cited by 8
“…the limitations of cytotoxic chemotherapy, targeted therapies have been formulated according to the molecular subtyping, such as the agents which target epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), and DNA mismatch repair pathways (Underwood et al. 2024).”
Signature Gene Mutations in Colorectal Cancer: Potential Neoantigens for Cancer Vaccines
Yoon, J., Moon, H., Jeon, Y., Choe, S., & Yoon, H. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26104559 · Cited by 7
“However, CRC exhibited the characteristics of a cold tumor due to its immunosuppressive TME, limiting its ability to induce an effective immune response in patients [2,13].”
Comparison of Machine Learning Models for Colon Cancer Survival: Predictive Modeling Approach
Adatorwovor, R., Ogunsanya, M. E., Huang, B., Charnigo, R. J., & Abraham, O. (2025) · JMIR Cancer · doi:10.2196/72665 · Cited by 7
“Nonetheless, newer treatment approaches such as targeted therapies, immunotherapies, and palliative care have improved survival and quality of life for patients with metastatic disease [29-31].”
Xu, M., Wang, H., Wang, W., Xing, Z., Lu, F., Yi, R., Ma, W., Aliswag, E. G., & Wu, J. (2024) · Supportive Care in Cancer · doi:10.1007/s00520-024-08883-8 · Cited by 12
Lee, S., Joo, S. H., Cho, S., Yoon, G., Choi, Y. H., Park, J. W., Weon, K.-Y., & Shim, J. (2025) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2024.123 · Cited by 7
Chen, S., Wang, Z., Sun, P., & Liu, Y. (2026) · APOPTOSIS · doi:10.1007/s10495-025-02239-1 · Cited by 6
Huo, L., Yue, H., Yang, R., Sun, X., Wang, Z., Liu, H., Liu, J., Feng, R., & Liang, P. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1643133 · Cited by 5
“Immunotherapy drugs primarily consist of nivolumab and Pembrolizumab (5).”
Song, D., Li, J., Zhu, Y., Hui, Q., Qi, H., Yu, H., Chen, L., Qian, Y., Guo, Y., Wei, M., et al. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03785-1 · Cited by 5
Liu, L., Zhang, C., Yang, B., & Wang, M. (2025) · Pathology - Research and Practice · doi:10.1016/j.prp.2025.155909 · Cited by 5
CXCL9 is a dual‑role biomarker in colorectal cancer linked to mitophagy and modulated by ALKBH5
Hu, G., Shen, S., & Zhu, M. (2025) · Molecular Medicine Reports · doi:10.3892/mmr.2025.13553 · Cited by 8
“However, issues such as off‑target effects and drug resistance remain significant chal ‑ lenges (11,12).”
Increased colorectal cancer risk in prediabetes: A meta-analysis
Wang, N., Zhao, T.-Y., & Ma, X. (2025) · World Journal of Diabetes · doi:10.4239/wjd.v16.i5.103403 · Cited by 4
Liu, T., Yao, R., Tong, Z., Dong, M., & Zhong, L. (2025) · Annals of Medicine · doi:10.1080/07853890.2025.2529573 · Cited by 4
“The National Comprehensive Cancer Network (NCCN) guidelines recommend the use of doublet or triplet therapy for patients who could tolerate an intensive therapeutic regimen, but how to choose maintenance treatment after these intensive chemotherapy was a valuable question [7].”
The colorectal liver metastasis growth pattern phenotype is not dependent on genotype
Höppener, D. J., Verheul, S. M. L., Nierop, P. M. H., Buisman, F. E., Galjart, B., Wilting, S. M., Pugh, S. A., Richman, S. D., Balachandran, V. P., Jarnagin, W. R., et al. (2025) · British Journal of Cancer · doi:10.1038/s41416-025-03103-4 · Cited by 4
“For metastatic colorectal cancer, KRAS , NRAS , and BRAF mutations are prognostically unfavourable and help select patients for EGFR inhibition [6].”
Lv, P., Ren, B., & Cheng, G. (2025) · Letters in Drug Design & Discovery · doi:10.1016/j.lddd.2025.100082 · Cited by 4
Cao, J., Hang, K., Tan, C., Wu, Z., Guo, Z., Xia, Q., Liao, D., Xia, Z., Men, J., & Li, K. (2025) · Biomaterials Advances · doi:10.1016/j.bioadv.2025.214600 · Cited by 4
Sawai, K., Goi, T., Kimura, Y., & Koneri, K. (2024) · Cancers · doi:10.3390/cancers16081556 · Cited by 4
“However, identifying the prognostic factors remains crucial for early detection of CRC recurrence and determination of efficacy to enhance treatment outcomes [2].”
BackgroundInfluence of Mesalazine on Ferroptosis-Related Gene Expression in In Vitro Colorectal Cancer Culture
Słoka, J., Strzałka‐Mrozik, B., Kubica, S., Nowak, I., & Kruszniewska‐Rajs, C. (2025) · Biomedicines · doi:10.3390/biomedicines13010219 · Cited by 4
“In certain cases, immunotherapy may also be considered [7,8].”
Tang, D., Orlandi, P., Li, Q., Bandini, A., & Bocci, G. (2025) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2025.189414 · Cited by 5
Yalçıner, M., Erdat, E. C., Kavak, E. E., & Utkan, G. (2025) · Discover Oncology · doi:10.1007/s12672-025-03974-2 · Cited by 4
“Despite significant advances in our knowledge of tumor biology and novel treatment strategies, metastatic CRC (mCRC) still poses a serious global health issue [2, 3].”
Zhou, X., Zhang, Q., Zhu, H., Zhao, J., & Cai, Y. (2024) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo-23-1016 · Cited by 6
“This is particularly evident in the treatment of advanced or metastatic CRC (mCRC), where the limitations of current therapies become more pronounced (9,10) .”
BackgroundMadej, M., Kruszniewska‐Rajs, C., Kimsa‐Dudek, M., Synowiec‐Wojtarowicz, A., Chrobak, E., Bębenek, E., Boryczka, S., Głuszek, S., Adamska, J., Kubica, S., et al. (2024) · Cells · doi:10.3390/cells13161368 · Cited by 4
“In some cases, immunotherapy is also possible [1,3].”
BackgroundHuang, Y., Cheng, N., Zhi, Y., Qiao, D., Wang, Y., Ma, M., Ge, C., Tao, W., & Liu, W. (2025) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2025.119759 · Cited by 4
Liu, X., Liu, W., Wu, Y., Wang, Y., Jiang, Q., Li, Y. Y., Li, H., & Hao, L. (2025) · Scientific Reports · doi:10.1038/s41598-025-03713-1 · Cited by 3
“Within the realm of targeted immunotherapy 32,33 , monoclonal antibodies such as anti-EGFR agents cetuximab and panitumumab 33–35 , along with the anti-VEGF bevacizumab 36 , have become mainstays in clinical practice.”
Aydemir, I., Çetindağ, E., Özmen, E., Kayıran, S. D., Kanan, D. D., Sakallı, E., Çınaroğlu, S., Dönmez, G., & Özkan, O. (2025) · Cytotechnology · doi:10.1007/s10616-025-00843-2 · Cited by 3
“VEGF, which particularly involves in the spread of tumor cells to https://doi.org/10.1007/s10616-025-00843-2 surrounding organs, also triggers other signaling molecules, enabling cell proliferation and migration (Malki et al. 2020; Underwood and Pawlik 2024; Underwood et al. 2024).”
InfluentialTur, R., Abad, M., Filipovich, E., Rivas, M. B., González, M. R., Montero, J. C., & Sayagués, J. M. (2025) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v17.i11.112838 · Cited by 5
Stojanović, B., Stojanović, B., Stojanovic, M. D., Cvetković, A., Milošević, B., Vulovic, V., Bevc, I. M., Jevtović, A., Tasić-Uroš, D., Knezevic, S., et al. (2026) · Cells · doi:10.3390/cells15060536 · Cited by 3
“These regimens are often administered alongside targeted therapies, guided by the molecular characteristics of the tumor [163].”
Seliger, B., Mantke, R., Naß, N., Dammermann, W., Ocvirk, S., Kah, J., Kalinski, T., & Massa, C. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27104299 · Cited by 3
“In clinical practice, currently actionable biomarkers guiding targeted therapy include components of the epidermal growth factor receptor (EGF-R) signaling pathway, like EGF-R, BRAF, and RAS [194], MSI-H/dMMR status, and rare NTRK fusions.”
Khorfan, R., Sedighim, S., Caba‐Molina, D., Tran, T. B., Senthil, M., O'Leary, M. P., & Eng, O. S. (2024) · Journal of Surgical Oncology · doi:10.1002/jso.27740 · Cited by 3
Design of Nanodrug Delivery Systems for Tumor Bone Metastasis
Zhai, X., Peng, S., Zhai, C., Wang, S., Xie, M., Guo, S., & Bai, J. (2024) · Current Pharmaceutical Design · doi:10.2174/0113816128296883240320040636 · Cited by 3
Synchronous rectal and endometrial cancer: A case report and literature review
Li, Z., Peng, L. W., Su, Q., & Zong, B. (2025) · Oncology Letters · doi:10.3892/ol.2025.15360 · Cited by 3
“However, the activation of HER2 signaling can lead to resistance to anti‑epidermal growth factor receptor therapy in a subset of patients with RC and RAS wild‑type tumors (25,26).”
Wang, S., Tang, J., Gan, L., & He, S. (2024) · Current Medicinal Chemistry · doi:10.2174/0109298673344265241014114804 · Cited by 2
Molecular pathways and targeted therapies in colorectal liver metastasis: from bench to bedside
Liu, F., Zhao, Y., & Jiao, Y. (2025) · Clinical & Translational Oncology · doi:10.1007/s12094-025-04038-1 · Cited by 2
“…vascularized organ, provides an ideal environment for metastasis, making angiogenesis a key factor in the progression of CRLM. Targeting VEGF and its receptors has become a therapeutic strategy aimed at inhibiting the blood supply to the tumor, thereby slowing down or halting tumor growth [5, 6].”
Habash, K., Turfa, R., Jaddoua, S. M., & Rabayah, A. A. (2025) · BMJ Open · doi:10.1136/bmjopen-2025-099635 · Cited by 2
Chen, Y., Ma, R., Wang, C., Yang, Z., Shi, Y., Zhao, Y., Pan, X., Wang, B., Wu, W., & Yuan, P. (2025) · Experimental Cell Research · doi:10.1016/j.yexcr.2025.114850 · Cited by 2
Yao, B., Yang, D., Fu, C., Deng, S., Yang, L., & Tian, L. (2025) · European journal of medical research · doi:10.1186/s40001-025-03649-2 · Cited by 3
Defining patients living long-term with incurable cancer: A modified hybrid Delphi study
Bouma, R., Stegmann, M., Raijmakers, N. J. H., van Zuylen, L., Reyners, A. K., van Asselt, K. M., van Gastel, M. D. A., Brandenbarg, D., & Geerse, O. P. (2025) · Palliative Medicine · doi:10.1177/02692163251400114 · Cited by 2
Bernacchi, A., Valerii, M. C., Spigarelli, R., Dussias, N. K., Rizzello, F., & Spisni, E. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27020649 · Cited by 3
“Drug resistance can be induced by the tumor microenvironment and by mutations within critical signaling cascades, such as the PI3K/AKT and Wnt pathways [11,12].”
Bai, G., Tao, Y., & Fan, M. (2026) · Immunopharmacology and Immunotoxicology · doi:10.1080/08923973.2026.2630162 · Cited by 3
Norepinephrine promotes colorectal cancer liver metastasis via mechanisms dependent on Kupffer cells
Li, Y., Zhi, J., Li, X., Liu, J., Yuan, N., Zhao, J., Wang, B., & Jia, Y. (2026) · International Immunopharmacology · doi:10.1016/j.intimp.2026.116449 · Cited by 2
Wang, B., Huang, X., Xing, Y., Jiao, W., Jiang, J., Liu, G., Li, G., Li, Q., Yang, C., & 史良会 (2026) · Cellular Signalling · doi:10.1016/j.cellsig.2026.112561 · Cited by 2
Anti-tumor activity of butorphanol in colorectal cancer via targeting SIGMAR1
Hou, X., Qu, L., Xu, Y., Liu, J., & Guo, J. (2024) · Discover Oncology · doi:10.1007/s12672-024-01581-1 · Cited by 2
“At present, curative resection integrated with chemoradiotherapy remain the mainstay curative approach for CRC patients, apart from which, immunotherapy and targeted therapy are also well established as novel treatment alternatives [4, 5].”
Wang, X., Li, Z., Sha, D., Ren, H., Yi, C., Li, S., Wang, P., Chu, Y., Li, C., Shan, G., et al. (2025) · The Oncologist · doi:10.1093/oncolo/oyaf129 · Cited by 3
Emerging treatment approaches for colorectal cancer treatment resistance
Mabonga, L., Fourie, R. L., Kappo, A. P., Lyantagaye, S., & Dlamini, Z. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-33475-7.00001-9 · Cited by 1
Wu, J., Li, Q., Cheng, X., Dai, C., Huang, Q., & Wang, Y. (2025) · Current Cancer Drug Targets · doi:10.2174/0115680096388633250704101500 · Cited by 1
Galloway, M., Awad, A. S., & Heilig, C. W. (2025) · Frontiers in Nephrology · doi:10.3389/fneph.2025.1586520 · Cited by 1
Simple porphyrin nanoparticles for combined photo-immunotherapy of colorectal cancer
Sun, H., Fan, Z., Pei, Q., Xie, Z., Zhang, T., & Ma, C. (2025) · Biomaterials Advances · doi:10.1016/j.bioadv.2025.214466 · Cited by 1
Li, Y., Liu, K., Lu, Y., & Gan, M. (2025) · Journal of Stomatology Oral and Maxillofacial Surgery · doi:10.1016/j.jormas.2025.102700 · Cited by 1
Zhang, H., Feng, J., Zhu, M., Shi, T., & Xi, Q. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-026-07995-5 · Cited by 1
“Nonetheless, CRC treatment still remains confronted with challenges such as large individual differences, drug resistance, and economic pressures [6].”
Wang, Q., Yao, L., Wang, B., Liu, X., & Chu, X. (2026) · Cytotechnology · doi:10.1007/s10616-026-00927-7 · Cited by 1
Post-marketing signal detection of fruquintinib-associated adverse events using the FAERS database
Liu, C., & Zhang, H. (2026) · Medicine · doi:10.1097/md.0000000000048239 · Cited by 1
“[1] Epidemiological data indicate significant geographic variations in the global incidence of CRC, with particularly high rates observed in high-and middle-income countries (HICs).”
Wang, C., Lin, W., Wu, C., Zhou, C., Gao, Y., Ma, Y., He, C., Wei, J., Li, L., Wu, R., et al. (2026) · Cytotechnology · doi:10.1007/s10616-026-00948-2 · Cited by 1
“Additionally, microsatellite instability (MSI) pathway also plays a vital role in the development of CRC, with MSI-high CRC exhibiting a significant response to PD-1 (Programmed Cell Death Protein 1) immune checkpoint inhibitors (Eng et al. 2022 , Underwood et al. 2024).”
Li, Z., Cheng, J., Zhao, X., Liu, Y., Zhang, Y., Li, Y., Zhao, Y., & Fan, C. (2026) · Clinics · doi:10.1016/j.clinsp.2026.100987 · Cited by 1
B3GNT6 suppresses colorectal cancer progression by inhibiting the KRAS/ERK signaling pathway
Jing, C., Wang, Z., Cao, H., Yu, Y., Li, B., & Ma, R. R. (2026) · BMC Biotechnology · doi:10.1186/s12896-026-01160-y · Cited by 1
“Despite advances in immuno-therapy and targeted therapies, the 5-year survival rate for CRC remains poor [16].”
Yu, J., Xiang, J., Lin, Y., Wang, S., Liu, Y., Chen, E., Liu, X., Wu, J., Wang, Y., & Zhao, L. (2026) · Clinical and Experimental Medicine · doi:10.1007/s10238-026-02193-5 · Cited by 1
Zhang, J., Zhao, X., & Wang, Y. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1838405 · Cited by 1
Yuan, S., Li, S., & Chen, C. (2026) · Biochemical Genetics · doi:10.1007/s10528-026-11392-4 · Cited by 1
“Current therapeutic approaches for localized tumors encompass surgical resection and adjuvant chemotherapy; however, the management of metastatic or recurrent cases remains challenging due to drug resistance and the limited efficacy of conventional therapies (Underwood et al. 2024 ).”
Achilleos, N., Harrison, M. T., & Tsiani, E. (2026) · Cancers · doi:10.3390/cancers18152391 · Cited by 1
Patterns of care in patients with asymptomatic stage IV colon cancer: A population-based analysis
Weaver, L., Tran, C. G., Kahl, A. R., Troester, A. M., Mishra, A., Prakash, A., Brauer, D. G., Charlton, M. E., Hassan, I., & Goffredo, P. (2025) · Surgery · doi:10.1016/j.surg.2025.109408 · Cited by 1
Surgical interventions and minimally invasive techniques in treatment-resistant colorectal cancer
Miya, T. V., Chipiti, T., Mabonga, L., Kader, S., & Dlamini, Z. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-33475-7.00004-4
Expression of SPNS2 in colorectal cancer and its role in colorectal cell proliferation and migration
Feng, X.-X., Wang, J.-J., & Dong, A. (2024) · World Chinese Journal of Digestology · doi:10.11569/wcjd.v32.i12.919
Stecko, H., Tsilimigras, D. I., Iyer, S., Daw, J., Zhu, H., Huang, E., Kalady, M. F., & Pawlik, T. M. (2025) · Journal of Gastrointestinal Surgery · doi:10.1016/j.gassur.2025.101990
Self-citationHuang, C., He, Y., Yang, Y., & Shen, W. (2025) · Current Cancer Drug Targets · doi:10.2174/0115680096357426250310070752 · Cited by 1
Stecko, H., Daw, J., Merritt, R. E., D’Souza, D. M., Baiu, I., Aziz, J. E., Rutter, C. E., Satija, D., Pawlik, T. M., & Kneuertz, P. J. (2025) · Research Square · doi:10.21203/rs.3.rs-6754101/v1
Self-citationHe, Q., Abulaiti, R., Feng, X., Tian, L., & Wang, K. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.152275
Perfil dos óbitos por neoplasia maligna de cólon nas regiões do Brasil no período de 2020 a 2024
Silveira, H. C. A., de Queiroz, E. A. I. F., & Alegranci, P. (2025) · Revista de Epidemiologia e Saúde Pública - RESP · doi:10.59788/resp.v3i1.162
Ai, M., Li, L., Fan, S., He, C., Guo, Y., & He, Y. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1605915
“In particular, for patients with left sided CRC, the combination of chemotherapy and targeted therapy can signi fi cantly prolong overall survival (9).”
Zhang, Z., Zheng, Q., Zhang, D., & Li, S. (2025) · Pharmacognosy Magazine · doi:10.1177/09731296251361618
“These unpleasant side effects drive the need to develop safer and more effective tumor-inhibiting agents (Underwood et al., 2024).”
Zhang, X., & Lu, J. (2025) · Biochemical Genetics · doi:10.1007/s10528-025-11244-7
Artificial Intelligence Driven Colorectal Cancer Classification via Deep Learning Technique
Nathiya, K., Ragunath, V., Swetha, S., & Gokul, V. (2025) · International Journal of Scientific Research in Computer Science Engineering and Information Technology · doi:10.32628/cseit25111709
Yang, C., Geng, X., & Zhao, Z. (2025) · PeerJ · doi:10.7717/peerj.20227
Xie, G.-L., Heng, J., Jia, X., Li, Q., Chang, R., Zhang, N., Xie, L., & Gao, C. (2025) · World Journal of Gastrointestinal Surgery · doi:10.4240/wjgs.v17.i10.109407
The importance of stromal cells in cancer: deciphering and modelling fibroblast subtype complexity
Jara Ortiz, F. D. L. (2025) · Radboud Repository (Radboud University)
Frontiers in thoracic oncology: new breakthroughs in molecular targets and immunotherapy
Yang, Y., Pu, D., & Li, X. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1721638
“The third-generation EGFR-TKI osimertinib was developed to target EGFR-T790M drug-resistant mutation, and has shown good ef fi cacy against drug-sensitive EGFR mutations (39 – 41).”
Chao, H., Liu, H., & Shen, W. (2025) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000001802
Mo, X., Wei, X., Mo, C., Kong, Y., Junqi, F., Deng, W., Xie, H., Wang, Q., Luo, W., Wei, C., et al. (2025) · Research Square · doi:10.21203/rs.3.rs-8240821/v1
Yuan, K., Bai, Y., Chen, S., Shi, Y., Yu, M., Zhang, K., Zhu, L. J., & Li, S. (2026) · Medicine · doi:10.1097/md.0000000000046783 · Cited by 1
“[59] These characteristics suggest that it may have significant value in the comprehensive treatment of cervical cancer.”
García-Arango, C., Reynoso‐Noverón, N., Ceballos, L. F. S., Islas, E. P., Guerrero, F. A., & Ríos, J. N. (2026) · Cancer Causes & Control · doi:10.1007/s10552-025-02120-1
Chen, Y., Deng, Q., Yang, L.-L., Jiang, A., Zhang, R., Yan, Q.-B., & Wu, Y. (2026) · Molecules · doi:10.3390/molecules31040622
“Systemic treatment is the primary treatment for CRC. Studies have demonstrated that targeted therapy and immunotherapy can effectively achieve tumor regression and improve survival rates [131].”
Antonoff, M. B., Hooda, Z., Sun, X., May, C., Evans, N. R., Grenda, T. R., Lee, J., Mehran, R. J., Okusanya, O. T., Rajaram, R., et al. (2026) · JTCVS Open · doi:10.1016/j.xjon.2026.101702
“Rates of crossover, treatment attrition, and feasibility challenges observed in this trial can help contextualize selection bias, treatment heterogeneity, and analytic assumptions in retrospective and observational datasets evaluating pulmonary metastasectomy.”
Molecular Mechanisms of Liver Metastasis: Connecting Biology, Biomarkers, and Outcomes
Wagner, D., Balzer, F., & Margonis, G. A. (2026) · Cells · doi:10.3390/cells15050469
“The subsequent contribution by Underwood and colleagues shifts attention toward therapeutic implications: as additional mutations and oncogenic proteins are discovered in metastatic colorectal cancer (mCRC), new targets for precision therapies will continue to emerge [3].”
Wu, P., Liu, G., Shao, L., & Wu, Y.-L. (2026) · Technology in Cancer Research & Treatment · doi:10.1177/15330338261430993
Metadata
- Authors
- Underwood, P. W., Ruff, S. M., & Pawlik, T. M.
- Affiliations
- The Ohio State University Wexner Medical Center (US)
- Corresponding author
- Pawlik, Timothy M.
- Venue
- Cells
- Publisher
- MDPI AG
- Published
- 2024-01-28
- Volume
- 13
- Issue
- 3
- Pages
- 245
- ISSN
- 2073-4409 (ISSN-L)
- PMC
- PMC10854977
- OpenAlex
- W4391314220
- Cited by
- 130
- References
- 89
- Citations by year
- 2026: 56 · 2025: 56 · 2024: 18
- FWCI
- 6.97
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Cells (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Keywords
- metastatic colorectal cancer, targeted therapy, immunotherapy, EGFR, vascular endothelial growth factor, DNA mismatch repair, molecular subtyping, tumor heterogeneity, genetic mutations, carcinogenesis, chemotherapy limitations
- MeSH terms
- Colonic Neoplasms, Humans, Immunotherapy, Rectal Neoplasms, Colorectal Neoplasms, Vascular Endothelial Growth Factor A
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-06, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-06 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.